Supplementary Table S1 from Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors

crossref(2023)

引用 0|浏览15
暂无评分
摘要

Supplementary Table S1 - PDF file 52K, Best overall tumor response (RECIST)

更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要